Risk factor management: Antiatherogenic therapies

European Journal of Cardiovascular Prevention and Rehabilitation

Volumn 16, Issue SUPPL. 2, 2009, Pages

  Gielen, Stephan ^a   Sandri, Marcus ^a   Schuler, Gerhard ^a   Teupser, Daniel ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTILIPEMIC AGENT; ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE MONONITRATE; LOW DENSITY LIPOPROTEIN; METHOTREXATE; METOPROLOL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ATHEROMA; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; EXERCISE; HEART PROTECTION; HUMAN; INTRAVASCULAR ULTRASOUND; LIFESTYLE MODIFICATION; MECHANOTRANSDUCTION; MEDICAL RESEARCH; MORTALITY; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SHEAR STRESS; STABLE ANGINA PECTORIS; VASCULITIS;

EID: 70349291322     PISSN: 17418267     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjr.0000359233.58023.64     Document Type: Review

References (49)

1. George BS. Combined coronary and peripheral intervention: the oculostenotic- dilatory reflex or good medicine? Catheter Cardiovasc Interv 2001; 52:105.
2. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356:1503-1516.
3. Tommaso CL. One year perspective on COURAGE. Catheter Cardiovasc Interv 2008; 72:426-429.
4. Pitt B, Waters D, Brown WV, van Boven J, Schwartz L, Title LM, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999; 341:70-76.
5. Katritsis DG, Ioannidis JP. Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: a meta-analysis. Circulation 2005; 111:2906-2912.
6. Cecil WT, Kasteridis P, Barnes JW Jr, Mathis RS, Patric K, Martin S. A metaanalysis update: percutaneous coronary interventions. Am J Manag Care 2008; 14:521-528.
7. Schomig A, Mehilli J, de WA, Seyfarth M, Pache J, Kastrati A. A metaanalysis of 17 randomized trials of a percutaneous coronary interventionbased strategy in patients with stable coronary artery disease. J Am Coll Cardiol 2008; 52:894-904.
8. Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F, et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27:1341-1381.
9. Ito K, Yamagishi M, Yasumura Y, Nakatani S, Yasuda S, Miyatake K. Impact of coronary artery remodeling on misinterpretation of angiographic disease eccentricity: evidence from intravascular ultrasound. Int J Cardiol 1999; 70:275-282.
10. Guedes A, Tardif JC. Intravascular ultrasound assessment of atherosclerosis. Curr Atheroscler Rep 2004; 6:219-224.
11. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003; 290:2292-2300.
12. Jensen LO, Thayssen P, Pedersen KE, Stender S, Haghfelt T. Regression of coronary atherosclerosis by simvastatin: a serial intravascular ultrasound study. Circulation 2004; 110:265-270.
13. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291:1071-1080. (Pubitemid 38541684)
14. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295:1556-1565.
15. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al., ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295:1556-1565
16. Glomset JA. The plasma lecithin: cholesterol acyltransferase reaction. J Lipid Res 1968; 9:155-167.
17. Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell: proloferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 1973; 180:1332-1339.
18. Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet 1975; 1:16-19.
19. Aiello RJ, Brees D, Bourassa PA, Royer L, Lindsey S, Coskran T, et al. Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages. Arterioscler Thromb Vasc Biol 2002; 22:630-637.
20. Braun A, Trigatti BL, Post MJ, Sato K, Simons M, Edelberg JM, et al. Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice. Circ Res 2002; 90:270-276.
21. Choi BG, Vilahur G, Yadegar D, Viles-Gonzalez JF, Badimon JJ. The role of high-density lipoprotein cholesterol in the prevention and possible treatment of cardiovascular diseases. Curr Mol Med 2006; 6:571-587.
22. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 2006; 22:2243-2250.
23. Sipahi I, Tuzcu EM. Candidate mechanisms for regression of coronary atherosclerosis with high-dose statins: insight from intravascular ultrasonography trials. Am J Cardiovasc Drugs 2008; 8:365-371.
24. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101:2149-2153.
25. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001; 103:491-495.
26. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836-843. (Pubitemid 30165206)
27. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347:1557-1565.
28. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352:20-28.
29. Morrow DA, de Lemos JA, Sabatine MS, Wiviott SD, Blazing MA, Shui A, et al. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation 2006; 114:281-288.
30. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-2207.
31. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359:1173-1177.
32. Bruckdorfer KR. Antioxidants and CVD. Proc Nutr Soc 2008; 67:214-222.
33. Ross J. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362:801-809.
34. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986; 315:1046-1051.
35. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98:1842-1847.
36. Wassmann S, Wassmann K, Nickenig G. Modulation of oxidant and antioxidant enzyme expression and function in vascular cells. Hypertension 2004; 44:381-386.
37. Crosby JR, Kaminski WE, Schatteman G, Martin PJ, Raines EW, Seifert RA, Bowen-Pope DF. Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation. Circ Res 2000; 87:728-730.
38. Li YS, Haga JH, Chien S. Molecular basis of the effects of shear stress on vascular endothelial cells. J Biomech 2005; 38:1949-1971.
39. Fleming I, Fisslthaler B, Dixit M, Busse R. Role of PECAM-1 in the shearstress- induced activation of Akt and the endothelial nitric oxide synthase (eNOS) in endothelial cells. J Cell Sci 2005; 118 (Pt 18):4103-4111.
40. Tzima E, Irani-Tehrani M, Kiosses WB, Dejana E, Schultz DA, Engelhardt B, et al. A mechanosensory complex that mediates the endothelial cell response to fluid shear stress. Nature 2005; 437:426-431.
41. Hambrecht R, Wolff A, Gielen S, Linke A, Hofer J, Erbs S, et al. Effect of exercise on coronary endothelial function in patients with coronary artery disease. N Engl J Med 2000; 342:454-460.
42. Hambrecht R, Adams V, Erbs S, Linke A, Kränkel N, Shu Y, et al. Regular physical activity improves endothelial function in patients with coronary artery disease by increasing phosphorylation of endothelial nitric oxide synthase. Circulation 2003; 107:3152-3158.
43. Adams V, Linke A, Kränkell N, Erbs S, Gielen S, Möbius-Winkler S, et al. Impact of regular physical activity on the NAD(P)H oxidase and angiotensin receptor system in patients with coronary artery disease. Circulation 2005; 111:555-562
44. Vasa M, Fichtlscherer S, Adler K, Aicher A, Martin H, Zeiher A, Dimmeler S. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary arthery disease. Circulation 2001; 103:r21-r26.
45. Sandri M, Adams V, Gielen S, Linke A, Lenk K, Krankel N, et al. Effects of exercise and ischemia on mobilization and functional activation of bloodderived progenitor cells in patients with ischemic syndromes: results of 3 randomized studies. Circulation 2005; 111:3391-3399.
46. Haskell WL, Lee IM, Pate RR, Powell KE, Blair SN, Franklin BA, et al. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Med Sci Sports Exerc 2007; 39:1423-1434.
47. Walter DH, Zeiher AM, Dimmeler S. Effects of statins on endothelium and their contribution to neovascularization by mobilization of endothelial progenitor cells. Coron Artery Dis 2004; 15:235-242.
48. Ceconi C, Fox KM, Remme WJ, Simoons ML, Bertrand M, Parrinello G, et al. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 2007; 73:237-246.
49. Hardoon SL, Whincup PH, Lennon LT, Wannamethee SG, Capewell S, Morris RW. How much of the recent decline in the incidence of myocardial infarction in British men can be explained by changes in cardiovascular risk factors? Evidence from a prospective population-based study. Circulation 2008; 117:598-604.